Published in Cancer Weekly, June 24th, 2003
Proprietary to Therion, Tricom consists of three costimulatory molecules designed to optimize the immune response necessary for tumor destruction when delivered as part of the company's pox virus-based vaccines. This approach, delivered in a "prime-boost" dosing regimen, induced tumor-specific immune responses and significant clinical benefit in some patients with CEA-expressing cancers (in this study, predominantly gastrointestinal cancers).
Specifically, disease stabilization...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.